✦ The Future BetsNarrow moat

Intuitive Surgical (ISRG) — the future bets

No moonshot — a feature Europe has not certified, a single-port system in its early stages, a digital layer with no price, and four governments deciding whether to pay.

Intuitive's future bets are unusually incremental, and that is a fair description of the company rather than a criticism. There is no adjacent market it is trying to enter and no acquisition strategy; the plan is to make the existing platform better, put it in more countries, and get more procedures onto it.

Four bets, none of them a moonshot870da Vinci 5placements in 2025377SP systems installed3.15Mprocedures feedingthe digital layer23%OUS proceduregrowthAll four monetise through the per-procedure toll that already exists.
Lower variance and lower ceiling than most future-bet branches here. Nothing depends on inventing a new business model.

The first is the generational upgrade, which is still in its early innings outside the United States. Da Vinci 5 reached 1,231 installed systems by the end of 2025 and was 870 of the year's 1,721 placements1, but Intuitive is running "a phased launch of our da Vinci 5 surgical system over several quarters" in international markets, and the European certification obtained in July 2025 explicitly excludes force feedback, for which the company will "intend to seek European certification for the use of force feedback in the future"2. The single most differentiated feature of the flagship is not yet approved in Europe.

The second is single-port. Da Vinci SP delivers three multi-jointed instruments and a fully articulating endoscope through one cannula, for single-incision or natural-orifice surgery3. Intuitive describes itself as "in the early stages of launching" it, with 377 systems installed at the end of 2025 and FDA clearance for urologic, colorectal, general thoracoscopic and certain transoral procedures. A measured European rollout began after certification in January 2024.

The third is the digital layer, and it is the one that could change the economics rather than the addressable market. Da Vinci 5 carries more than 10,000 times the computing power of its predecessor and connects to Case Insights, Intuitive Hub, SimNow and the My Intuitive app4; in October 2025 the FDA cleared a software release introducing artificial intelligence "across Ion's entire navigational workflow"5. A company that already sees several million procedures a year has the largest surgical dataset in existence and has barely begun charging for what it knows.

The fourth is geography, and it is the largest number on this page. Outside-the-United-States procedures grew 23% in 2025 against 15% domestically, with particular strength in South Korea and India6, and the company expects OUS to become a greater share of the business over time. Japan expanded reimbursement on 1 June 2026, largest category inguinal hernia, and Japanese placements went from 15 to 25 in a quarter7.

None of these transforms the company. What they do is determine whether procedure growth returns to the high teens after 2026, which is the only question the valuation actually turns on.

Moat trajectory: Widening

Force feedback shipping in the flagship, single port at 377 systems, a digital layer built on the largest surgical dataset in existence, and 23% of revenue outside America with Japan and China both moving. Modest bets, all of them progressing.

The number that tests this moat
Reported
Research and development expense
$1,311.8M in 2025, 13.0% of revenue, up 15%

All four bets are paid for out of this line and monetised through the same per-procedure toll. R&D falling as a share of revenue while rivals arrive would say the next generation is being underfunded.

Source: Intuitive Surgical Form 10-K, FY2025 ↗
✦ Future bets — beyond today's moat
✦ FUTURE BET 01
Force Feedback, and the Certification Europe Has Not Given
The flagship's distinguishing feature is explicitly excluded from its European certification.
✦ FUTURE BET 02
Single Port, and the Operations That Do Not Exist Yet
377 systems opening procedures where the alternative is a larger incision rather than a better laparoscope.
✦ FUTURE BET 03
The Digital Layer
The largest surgical dataset in existence, and no disclosed price for anything built out of it.
✦ FUTURE BET 04
Twenty-Three Percent Outside America
One Japanese reimbursement decision took quarterly placements from 15 to 25 — the mirror image of what Washington did.
References
  1. ReportedDa Vinci 5 reached 1,231 installed systems by the end of 2025 and was 870 of the year's 1,721 placements, but Intuitive is running "a phased launch of our da Vinci 5 surgical system over several quarters" in international markets, and the...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedDa Vinci 5 reached 1,231 installed systems by the end of 2025 and was 870 of the year's 1,721 placements, but Intuitive is running "a phased launch of our da Vinci 5 surgical system over several quarters" in international markets, and the...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedDa Vinci SP delivers three multi-jointed instruments and a fully articulating endoscope through one cannula, for single-incision or natural-orifice surgery.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  4. ReportedDa Vinci 5 carries more than 10,000 times the computing power of its predecessor and connects to Case Insights, Intuitive Hub, SimNow and the My Intuitive app; in October 2025 the FDA cleared a software release introducing artificial...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedDa Vinci 5 carries more than 10,000 times the computing power of its predecessor and connects to Case Insights, Intuitive Hub, SimNow and the My Intuitive app; in October 2025 the FDA cleared a software release introducing artificial...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  6. ReportedOutside-the-United-States procedures grew 23% in 2025 against 15% domestically, with particular strength in South Korea and India, and the company expects OUS to become a greater share of the business over time.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  7. ReportedJapan expanded reimbursement on 1 June 2026, largest category inguinal hernia, and Japanese placements went from 15 to 25 in a quarter.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
Sources
Generated September 23, 2026